Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Interest & Investment Income of -$9000.0 for Q4 2025, down 100.22% year-over-year from $4.1 million in Q4 2024, and down 100.53% quarter-over-quarter from $1.7 million in Q3 2025.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at -$9000.0 for Q4 2025.
- In Q4 2025, Interest & Investment Income fell 100.22% year-over-year to -$9000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 79.69% YoY), while the FY2025 annual figure was -$62000.0, down 100.31% from the prior year.
- Interest & Investment Income for Q4 2025 stood at -$9000.0, down from $1.7 million in the prior quarter.
- The five-year high for Interest & Investment Income was $4.2 million in Q3 2024, with the low at -$284000.0 in Q3 2022.
- The 4-year median for Interest & Investment Income is $64000.0 (2023), against an average of $756142.9.
- Peak annual rise in Interest & Investment Income reached 2972.26% in 2024, while the deepest fall reached 113.66% in 2024.
- Neumora Therapeutics' Interest & Investment Income stood at $380000.0 in 2022, then slumped by 38.16% to $235000.0 in 2023, then jumped by 1639.57% to $4.1 million in 2024, then slumped by 100.22% to -$9000.0 in 2025.
- Business Quant data shows NMRA's Interest & Investment Income at -$9000.0 in Q4 2025, $1.7 million in Q3 2025, and -$12000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Neumora Therapeutics | 245.34 Mn | 245.34 Mn | - | 935,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 935,000.00 |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Mar 31, 2025 | -65,000.00 |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -65,000.00 |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | -150,000.00 |
| Mar 31, 2023 | 476,000.00 |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 1.41 Mn |